MM logo

Multiple Myeloma

Data from the IMAGE study support real-world use of isatuximab in patients with relapsed/refractory multiple myeloma, with findings similar to those reported for ICARIA-MM. Read More ›

Patient-reported outcomes with ciltacabtagene autoleucel are consistent with clinical findings and support its use in heavily pretreated patients with relapsed/refractory multiple myeloma. Read More ›

Iberdomide, a novel cereblon E3 ligase modulator, in combination with dexamethasone showed encouraging results in a multicohort, open-label, phase 1/2 trial. Read More ›

Iberdomide and mezigdomide have shown to be more potent than traditional immunomodulators and may have potential as new oral agents in multiple myeloma. Read More ›

Recent initiative to boost new technologies in oncology focuses on the impact of blood testing as a major area of interest in better understanding multiple myeloma. Read More ›

Decreasing mortality has been seen since the mid-1990s in patients with multiple myeloma due to intensification of frontline therapies. Read More ›

Single-agent belantamab mafodotin shows anti-myeloma activity in heavily pretreated patients with relapsed/refractory multiple myeloma. Read More ›

Early IONA-MM data show promising real-world evidence of the benefits of isatuximab in patients with relapsed/refractory multiple myeloma. Read More ›

New treatment options are under consideration for consolidation and maintenance therapy after autologous stem-cell transplantation in newly diagnosed patients with multiple myeloma. Read More ›

A single infusion of ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma resulted in an overall response rate of 95%. Read More ›

Page 1 of 12

Subscribe Today!

To sign up for our free e-Newsletter or print publications, please enter your contact information below.

I'd like to receive:

OPM e-Newsletter
OPM print publication